TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Everolimus (RAD001) Compared to Placebo in Patients With Advanced Neuroendocrine Tumors

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~1. Patients must have advanced (unresectable or metastatic) biopsy-proven pancreatic NET~2. Measurable disease by radiologic assessment~3. Adequate blood work~4. Performance Status 0-2 : Ability to be out of bed most of the time~5. Adult male or female patients ≥ 18 years of age~6. Women of childbearing potential must have a negative serum pregnancy test~7. Written informed consent from patients must be obtained in accordance to local guidelines~Exclusion criteria:~1. Patients with severe kind of (poorly differentiated neuroendocrine carcinoma, high-grade neuroendocrine carcinoma, adenocarcinoid, goblet cell carcinoid and small cell carcinoma) cancer are not eligible~2. Other chemotherapy, immunotherapy or radiotherapy within 4 weeks prior to starting this trial~3. Hepatic artery procedure called embolization within the last 6 months (1 month if there are other sites of measurable disease), or cryoablation/ radiofrequency ablation of hepatic metastasis within 2 months of enrollment~4. Prior therapy with the same kind of medication (mTOR inhibitors: sirolimus, temsirolimus, everolimus).~5. Uncontrolled diabetes mellitus Patients who have any severe and/or uncontrolled medical conditions such as:~6. Patients receiving chronic treatment with corticosteroids or another immunosuppressive agent~7. Patients with a known history of HIV seropositivity~8. No other prior or concurrent cancer at the time enrolling to this trial~Other protocol defined inclusion/ exclusion criteria applied

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Everolimus 10 mg/day (Type: EXPERIMENTAL): Participants received 10 mg per day of Everolimus plus best supportive care. Patients received their first dose of everolimus at Visit 2 (Cycle 1 Day 1).
- Placebo (Type: PLACEBO_COMPARATOR): Participants received matching placebo to everolimus daily plus best supportive care. Patients received their first dose of matching placebo at Visit 2 (Cycle 1 Day 1).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Chronic Graft Versus Host Disease

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Steroid dependent or refractory classic chronic GVHD disease.~* No more than 3 previous treatments for cGVHD.~* Receiving baseline systemic glucocorticoid therapy (at stable dose) for cGVHD at study entry.~* Men and women ≥18 years old.~* Karnofsky performance status ≥60.~Exclusion Criteria:~* Known or suspected active acute GVHD.~* Current treatment with sirolimus AND either cyclosporine or tacrolimus.~* History of treatment with a tyrosine kinase inhibitor (eg, imatinib), purine analogs or other cancer chemotherapy in the 4 weeks prior to starting study drug.~* Currently active, clinically significant cardiovascular disease.~* Uncontrolled infections not responsive to antibiotics, antiviral medicines, or antifungal medicines or a recent infection requiring systemic treatment that was completed ≤14 days before the first dose of study drug.~* Progressive underlying malignant disease including post-transplant lymphoproliferative disease.~* History of other malignancy (not including the underlying malignancy that was the indication for transplant)~* Concomitant use of warfarin or other Vitamin K antagonists~* Known bleeding disorders or hemophilia.~* History of stroke or intracranial hemorrhage within 6 months prior to enrollment.~* Known history of human immunodeficiency virus (HIV) or active with hepatitis C virus (HCV) or hepatitis B virus (HBV).~* Concurrent use of a strong cytochrome P450(CYP) 3A inhibitor.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Phase 1b: Dose Level 1 (Type: EXPERIMENTAL): Subjects receive daily dose of 420 mg of Ibrutinib capsules
- Phase 1b: Dose Level 2 (Type: EXPERIMENTAL): Subjects receive daily dose of 280 mg of Ibrutinib capsules
- Phase 1b: Dose Level 3 (Type: EXPERIMENTAL): Subjects receive daily dose of 140 mg of Ibrutinib capsules
- Phase 2 (Type: EXPERIMENTAL): Subjects receive daily dose of recommended phase 2 dose

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Clinical Outcomes After Bowel Resection in Patients Receiving Alvimopan Versus Patients Not Receiving Alvimopan in the Premier Perspective Database

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* ≥ 18 years at discharge~* Medical claim with an ICD-9-CM procedure code for a primary procedure (identified at position 1 or 2 involving large or small segmental bowel resection with primary anastomosis~* Discharged within the study dates~* Surgery at a participating Premier/Care Sciences hospital~Exclusion Criteria:~* Had a diverting ostomy without a primary anastomosis during the index hospitalization~* Had a trauma diagnosis~* Had bowel resections performed on more than 1 day during index hospitalization (this includes cases where a bowel resection and intestinal anastomosis were performed on different days during the index hospitalization)~* Had an excluded non-bowel resection surgical code (i.e., code for a major non-BR surgical procedure \[eg., nephroureterectomy, total joint replacement\] in position 1 or 2

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Alvimopan Users (Type: None): None
- Matched controls (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Bleeding Incidence in VWD Patients Undergoing On-Demand Treatment

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~Patients who meet all of the following criteria are eligible for the study:~* Male or female patients aged ≥5.5 years at the time of enrolment~* VWD type 1 (baseline von Willebrand factor activity \[VWF:RCo\], \<30 IU/dL), 2A, 2B, 2M, or 3 according to medical history requiring substitution therapy with a VWF-containing product to control bleeding~* Currently receiving frequent on-demand treatment with a VWF-containing product~* In female patients of child-bearing potential using hormonal contraception, the medication class should remain unchanged for the duration of their study participation~* Voluntarily given, fully informed written and signed consent obtained before collection of any patient data~Exclusion Criteria:~Patients who meet any of the following criteria are not eligible for the study:~* Patients currently on prophylaxis for VWD (except for perioperative prophylaxis) as well as patients having received treatment once a month for menstrual bleeding, but not for any other bleeds~* Patients whose VWD treatment is planned to be switched from on-demand to prophylactic treatment in the next 6 months~* History, or current suspicion, of VWF or FVIII inhibitors~* Medical history of a thromboembolic event within 6 months before enrolment~* Severe liver or kidney diseases as described in the medical records~* Female patients with an existing or suspected pregnancy or who are breast-feeding at the time of enrolment~* Change in hormonal contraception within 6 months before enrolment~* Cervical or uterine conditions causing abnormal uterine bleeding (including infection or dysplasia)~* Other coagulation disorders or bleeding disorders due to anatomical reasons~* Participation in an interventional clinical study during the 6-month of study period~* Inability to complete the patient diary to reliably evaluate the type, frequency, and treatment of BEs during the 6-month study period

- Gender: ALL
- Minimum Age: 66 Months
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Patients undergoing treatment with a VWF-containing product (Type: None): Patients with type 3, type 2 (except 2N), or severe type 1 VWD undergoing routine on-demand treatment with a VWF-containing product over a period of 6 months

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Combination Bisphosphonate and Anti-Angiogenesis Therapy With Pamidronate and Thalidomide

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients must have a diagnosis of Smoldering or Indolent myeloma~* All patients must be informed of the investigational nature of this study and must sign a written informed consent in accordance with UAMS Human Research Advisory Committee and federal guidelines.~Exclusion Criteria:~* Prior bisphosphonate therapy within 30 days prior to study entry.~* Serum creatinine \> 5 mg/dl, ascites, or serum direct bilirubin \> 2.5 mg/dl.~* Prior plicamycin or calcitonin within 2 weeks of study entry.~* Severe cardiac disease, unstable thyroid disease, or epilepsy.~* Prior radiation therapy to \> 20% of the skeleton.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Thalidomide + Bisphosphonate (Type: EXPERIMENTAL): 200 mg/day Thalidomide + 90 mg Pamidronate OR 4 mg Zometa every 2 weeks for 2 months and then every 4 weeks as maintenance therapy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Prospective Randomized Controlled Study of Intravitreal Injection of Bevacizumab for Proliferative Diabetic Retinopathy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Clinical diagnosis of Proliferative Diabetic Retinopathy (PDR)~* Indicated for vitrectomy~Exclusion Criteria:~* History of intraocular surgery, intravitreal injection of drugs or sub-Tenon injection of steroids or retinal photocoagulation within 6 months

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Bevacizumab injection and vitrectomy (Type: ACTIVE_COMPARATOR): 0.16 mg/0.05 ml bevacizumab intravitreal injection one day before vitrectomy.
- Sham injection and vitrectomy (Type: SHAM_COMPARATOR): Sham injection one day before vitrectomy.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Lenalidomide Dose Escalation Combined With Rituximab/Fludarabine in Untreated CLL

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* B-CLL (CD23+, CD5+, CD19+, CD20+)~* Treatment indication according to NCI criteria~* Age \>= 18 yrs~* No previous treatment of CLL by chemo-, radio- or immunotherapy~* Life expectancy \> 6 months~* Written informed consent~* Women of non-childbearing potential or women of childbearing potential and men using effective contraception~Exclusion Criteria:~* Active bacterial, viral or fungal infection~* Positivity for HIV, Hepatitis B or C~* Reduce organ functions and bone marrow dysfunction not due to CLL~* Creatinine clearance below 30 ml/min~* Patients with medical conditions requiring long-term use of systemic corticosteroids during study treatment~* Patients with a history of severe cardiac disease~* Other known co-morbidity with the potential to dominate survival~* Transformation to aggressive B-cell malignancy~* Known hypersensitivity to humanised monoclonal antibodies or any of the study drugs~* Pregnant or breast-feeding women~* Any co-existing medical or psychological condition that would preclude participation in the study or compromise ability to give informed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment Arm (Type: EXPERIMENTAL): Lenalidomide Dose Escalation combined with Fludarabine/Rituximab followed by maximum tolerated lenalidomide dose/Rituximab maintenance therapy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Roll-Over Study of Ivacaftor in Cystic Fibrosis Pediatric Subjects With a CF Transmembrane Conductance Regulator Gene (CFTR) Gating Mutation

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria (Ivacaftor Arm):~1. Completed the last study visit of the treatment period of the previous study (NCT01705145)~2. Hematology, serum chemistry, and vital signs results on Day 1 with no clinically significant abnormalities that would interfere with the study assessments, as judged by the investigator~3. As judged by the investigator, parent or legal guardian must be able to understand protocol requirements, restrictions, and instructions and the parent or legal guardian should be able to ensure that the subject assents to participation in the study to the degree the subject can assent, and that the subject will comply with and is likely to complete the study as planned~Inclusion Criteria (Observational Arm):~1. Subjects who completed their assigned study drug treatment in the previous study (NCT01705145) and elected not to enroll in the ivacaftor arm and subjects who prematurely discontinued treatment in the previous study and received at least 1 dose of study drug treatment in the previous study will be eligible for enrollment in the observational arm.~Exclusion Criteria (Ivacaftor Arm):~1. Subjects who prematurely discontinued from the previous study~2. History of any illness or condition that, in the opinion of the investigator, might confound the results of the study or pose an additional risk in administering study drug to the subject~3. Subjects with a history of study treatment intolerance as observed in their previous study that, in the opinion of the investigator, might pose an additional risk in administering study drug to the subject~4. Subjects receiving commercially-available ivacaftor treatment~5. Subject was unable to complete an adequate slit-lamp examination at the last ophthalmologic examination in the previous study~Exclusion Criteria: (Observational Arm)~1. Subjects receiving ivacaftor treatment will not be eligible for enrollment in the observational arm.

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Observational Arm (Type: NO_INTERVENTION): None
- Ivacaftor (Type: EXPERIMENTAL): Ivacaftor will be administered every 12 hours (q12h) from Day 1 through the Week 84 Visit. The ivacaftor dose will be:~* 50 mg q12h for subjects 2 to \<6 years of age and \<14 kg,~* 75 mg q12h for subjects 2 to \<6 years of age and ≥ 14 kg, or~* 150 mg q12h for subjects ≥ 6 years of age.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Defibrotide for the Treatment of Severe Hepatic Veno-Occlusive Disease in Hematopoetic Stem Cell Transplant Patients

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Clinical diagnosis of VOD, defined by jaundice (bilirubin \>/= 2 mg/dL) and at least 2 of the following clinical findings, by Day+21 post stem cell transplant: ascites; weight gain \>/= 5% above baseline weight; hepatomegaly.~* Severe VOD, defined as VOD with multi-organ failure, i.e., presence of one or both of the following, by Day+28 post stem cell transplant: renal or pulmonary dysfunction.~* Provide voluntary written informed consent.~Exclusion Criteria:~* Pre-existing (prior to SCT) cirrhosis~* An alternative diagnosis for weight gain, ascites and jaundice~* Graft-versus-host disease (GVHD) grade B or higher involving liver or gut or grade C or higher involving skin~* Prior solid organ transplant~* Dependent on dialysis prior to and/or at the time of SCT~* Dependent on oxygen supplementation prior to SCT~* Significant acute bleeding or hemodynamic instability~* Requirement for the use of any medications that increase risk of hemorrhage will be excluded from the treatment group

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Defibrotide (Type: EXPERIMENTAL): Defibrotide treatment
- Historical Control (Type: NO_INTERVENTION): Historical control group

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Anticoagulation With Enhanced Gastrointestinal Safety

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria for Patients:~* Enrollment with the Michigan Medicine anticoagulation monitoring service~* Currently prescribed warfarin with anticipated use for ≥90 days on day 1 of trial enrollment, according to the electronic health record documentation.~* Currently prescribed an antiplatelet medication (aspirin, clopidogrel, ticagrelor, or prasugrel) according to the electronic health record medication list~Inclusion Criteria for Clinicians:~* Cardiologists at Michigan Medicine who in the prior year had a face-to-face or virtual visit with a patient who meets eligibility criteria~* Michigan Medicine primary care providers for patients who meet eligibility criteria~* Clinicians in any specialty who are designated as the clinician of record with the anticoagulation clinic for a patient who meets eligibility criteria~Exclusion Criteria for Patients:~* Age less than 18~* Currently prescribed a PPI~* Documented intolerance or allergy to PPI use~* Left ventricular assist device~* Heart transplant~* Participation in a previous pilot study of these implementation strategies~Exclusion Criteria for Clinicians:~* Cardiologists specializing in electrophysiology or who saw the patient for a clinic visit related to a TAVI procedure unless they are the clinician of record for a patient followed by the anticoagulation service who does not have a Michigan Medicine PCP.~* Participation in a previous pilot study of these QI strategies

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Clinician Notification with Nurse Facilitation (CNNF) (Type: EXPERIMENTAL): None
- Wait List Control (Usual care) (Type: OTHER): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Immunogenicity and Safety of NBP608 Compared to Zostavax in Healthy Adult Aged 50 and Over

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy adult over aged 50 years~* Menopause females or females who are confirmed to be negative in a preganacy test on the day of screening and agree to practice birth control for 6 weeks after signing informed concent~Exclusion Criteria:~* Those with hypersensitivity to any component of IP(Investigational Product), such as gelatin~* Those with a history of hypersensitivity to vaccination, such as Guillain-Barre syndrome~* Those who have received antiviral agents witin 1 month prior to IP vaccination (topical antiviral agent is allowed)~* Those who have previously received herpes zoster vaccine~* Those who have a history of herpes zoster~* Those with congenital or acquired immunodeficiency~* Those with active untreated tuberculosis~* Those who have received blood products or immunoglobulin within 3 months prior to IP(Investigational Products) vaccination~* Those who have received other IPs(Investigational Products) in another clinical study witin 4 weeks prior to IP vaccination in this study

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- NBP608 (Type: EXPERIMENTAL): Single dose 0.5mL of NBP608 by subcutaneous injection into the outer aspect of the upper arm
- Zostavax (Type: ACTIVE_COMPARATOR): Single dose 0.65mL of Zostavax by subcutaneous injection into the outer aspect of the upper arm

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Pharmacokinetics of Atazanavir/Ritonavir in HIV-1 Infected Pregnant Women

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* HIV-infected pregnant women~* \> 18 years of age~* Between week 12 and 32 gestation~* CD4 \> 200 cells/mm³~* Treatment-naive with HIV RNA \> 400 c/mL, on HAART with HIV RNA \<50 c/mL, or previously treated with ATV (\< 3 weeks) with HIV RNA\>400 c/mL

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete